Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oman Healthcare News.
Press releases published on September 3, 2025
Molecular Assay Market to Grow at a CAGR of 7% During the Forecast Period (2025 – 2030): Wissen Research
Sheridan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- According to the latest market report published by Wissen Research, the global molecular assay market was valued at USD 16.4 billion in 2024. Furthermore, the market is expected to grow at a CAGR of 7% during …
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference …
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being …
Sotera Health Announces Secondary Offering of Common Stock
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares …
Artelo Biosciences Announces Proposed Underwritten Public Offering
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage …
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment
Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP : 23306J309), une …
Pennant Announces Home Health Acquisition in Wyoming
EAGLE, Idaho, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that effective September 1, 2025, it …
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 …
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that …
Surrozen to Present at Upcoming Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye …
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of …
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights …
Radiance Biopharma Signs Exclusive License For ‘First In Class’ c-Met/EGFR Targeted Nano Antibody ADC
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement with Novatim Immune Therapeutics (Zhejiang) CO., LTD. , (“ …
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized …